Celebrating Rare Disease Day 2019

In less than two weeks we will start celebrating Rare Disease Day – that annual day when all those who are affected by a rare disorder go out and speak about it. The global rare disease community holds celebrations throughout the world. This year TreatSMA will take part with an online campaign and a face-to-face event in the South East.

The 29th February is the rarest day in the calendar. It has become the day to celebrate and build awareness of rare diseases, which in Europe mean diseases that individually affect fewer than one in 2,000 people. When there is no 29th February in the given year, celebrations are held on the 28th – always the last day of the month.

Spinal muscular atrophy is a rare disorder as it affects one person in around 10,000.

The idea of a special day to build awareness of rare diseases came from EURORDIS, the European Organisation for Rare Diseases which started the tradition in 2008. Throughout the years, EURORDIS have been very supportive of the SMA community’s efforts to secure broad approvals for SMA therapies, was one more way they were intertwinned with SMA.

On Tuesday 26th February, TreatSMA along with 11 other rare disease organisations will have a stall at the Rare Disease Day at the Royal Holloway in Egham, Surrey. We will talk about living with SMA and about our ongoing battle for treatment. While there are no more tickets left, you can join the global efforts by spreading the word online – sharing the attached poster and leaflet and encouraging people to visit www.rarediseaseday.org.

Rare Disease Day 2019 – Information Pack

Rare Disease Day – Flyer

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more